Fresh analysis suggests that patients who come off new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise plans.
Published data in a major medical journal demonstrates that while obese individuals frequently drop a large proportion of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Individuals purchasing such treatments need to be aware of the danger of quick weight regain when the therapy ends," warns researcher Dr. Susan Jebb.
Such speed of regain means a return to starting weight within about 18 months.
Comparing Treatments
The research, which looked at 37 of studies involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
The team note that individuals who shed pounds through diet and exercise usually experience a less rapid weight regain—around 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Nutrition scientists suggest the way of the drugs explains the heightened rebound.
The injections imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 levels far above than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement leads to hunger is unsuppressed, making overeating much more probable."
A Chronic Disease?
Medical guidelines advise the injections for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, considering the likelihood of weight regain, the treatment is often life-long.
This perspective is echoed by pharmaceutical companies, who say that the results "highlight the chronic character of obesity," akin to managing conditions like hypertension.
Patient Testimonies
Users who have come off the jabs explain a intense return of hunger.
"I experienced something activating and you become ravenous," described one woman.
This difficulty is compounded if users have not established permanent lifestyle or habit modifications during treatment.
Significant Use
Figures suggest that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is higher among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Finally, experts caution that while GLP-1 drugs are effective agents for shedding pounds, they are not a standalone cure and lasting health benefits hinges on combined behavioural management.
